ERBB2 and neoplasm: In HER2-positive (IHC 3+) breast cancer patient-derived xenograft models named MAXF1322 and MAXF1162, SYD985 dose dependently reduced tumor growth, whereas high dose trastuzumab did not show any antitumor activity.